IHH Healthcare, a leading global healthcare provider, has introduced a $5m Research Grant & Innovation Sandbox programme to bolster clinical research and innovation across its international network. The fund, distributed over five years, is designed to empower IHH clinicians and employees to develop groundbreaking ideas that address pressing health issues, with a focus on improving patient experiences and outcomes.
The initial grant call, launched in March, targeted oncology and chronic diseases, two critical areas in global health. From 55 submissions, the Grant Governance Committee, comprising senior management and domain experts, shortlisted seven Research Grant projects and eight Innovation Sandbox applications. These projects are expected to be completed within one to two years, contributing to the broader healthcare literature on these diseases.
The Innovation Sandbox track prioritises projects with clear impacts, such as scalability, cost savings, and enhanced patient outcomes. “The launch of our first Research Grant & Innovation Sandbox marks a pivotal step in our multiyear transformation journey to become a global healthcare leader,” said Dr Prem Kumar Nair, Group CEO of IHH Healthcare. “I am inspired by the ingenuity of our teams and the calibre of ideas they have brought forward.”
IHH Healthcare plans to open its next call for submissions in September, continuing its commitment to fostering internal innovation and shaping the future of healthcare. Through its trusted brands, including Acibadem, Mount Elizabeth, and Gleneagles, IHH aims to deliver comprehensive and personalised care across its key markets.
“`
